Illana Gozes, Alistair Stewart, Bruce Morimoto, Anthony Fox, Karole Sutherland and Donald Schmechel Pages 455 - 460 ( 6 )
AL-108 is the intranasal formulation of NAP (a peptide of eight amino acids, NAPVSIPQ). Phase IIa clinical results have recently shown that AL-108 has a positive impact on memory function in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimers disease (AD). The clinical development of AL-108 has been based on extensive studies showing pre-clinical efficacy for NAP. NAP has demonstrated potent neuroprotective activity in vitro and in vivo. Its mechanism of action is thought to center on the modulation of microtubule stability in the face of outside damage. Such an effect on structures of such central importance in a broad range of cellular functions is thought to explain NAPs activity in wide ranging models of cellular damage and neurodegeneration. The following article reviews NAPs discovery and pharmacological characterization that has led to clinical development of a novel tangle-directed drug candidate., Addressing, Alzheimers, Disease, Tangles:, From, NAP, to, AL-108
Lily and Avraham Gildor Chair for the Investigations of Growth Factors, Director, The Adams Super Center for Brain Studies, Levi-Edersheim-Gitter Institute for Functional Brain Imaging, Head, The Elton Laboratory for Neuroendocrinology; Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.